Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 2/2015

Open Access 01-04-2015 | Review

Novel antibiotics: Are we still in the pre–post-antibiotic era?

Authors: R. Draenert, U. Seybold, E. Grützner, J. R. Bogner

Published in: Infection | Issue 2/2015

Login to get access

Abstract

Purpose

Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed.

Methods

This paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials.

Conclusion

Each of these new trials increases the possibility of new antibiotics receiving approval.
Literature
1.
Dalhoff A. Resistance surveillance studies: a multifaceted problem—the fluoroquinolone example. Infection. 2012;40:239–62.CrossRefPubMed
2.
Lubbert C, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case–control analysis. Infection. 2014;42:309–16.CrossRefPubMed
3.
Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54:S214–9.CrossRefPubMed
4.
Rubino CM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53:4422–8.CrossRefPubMedCentralPubMed
5.
Belley A, et al. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2013;57:205–11.CrossRefPubMedCentralPubMed
6.
Dunbar LM, et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55:3476–84.CrossRefPubMedCentralPubMed
7.
Corey GR, Jiang H, Moeck G. Dalbavancin or oritavancin for skin infections. N Engl J Med. 2014;371:1162–3.PubMed
8.
Seltzer E, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37:1298–303.CrossRefPubMed
9.
Jauregui LE, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407–15.CrossRefPubMed
10.
Raad I, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40:374–80.CrossRefPubMed
11.
Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother. 2006;58:627–31.CrossRefPubMed
12.
Dorr MB, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005;55:ii25–30.CrossRefPubMed
13.
Boucher HW, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–79.CrossRefPubMed
14.
Flanagan S, Passarell J, Lu Q. Tedizolid population pharmacokinetics, exposure–response, and target attainment. Antimicrob Agents Chemother. 2014;58:6462–70.CrossRefPubMed
15.
Liapikou A, et al. New antimicrobial approaches to gram positive respiratory infections. Pulm Pharmacol Ther. 2014 (Epub ahead of print).
16.
Moran GJ, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14:696–705.CrossRefPubMed
17.
Rybak JM, Marx K, Martin CA. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy. 2014;34:1198–208.CrossRefPubMed
18.
19.
Flanagan S, Minassian SL, Morris D. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014;58:6471–6.CrossRefPubMed
20.
Beringer P, et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005;49:3676–81.CrossRefPubMedCentralPubMed
21.
Shorr AF, et al. Analysis of the phase 3 ESTABLISH trials: tedizolid versus linezolid in acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 2015;59:864–71.CrossRefPubMedCentralPubMed
22.
Flamm RK, et al. Ceftazidime–avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microb Infect Dis. 2014;80:233–8.CrossRef
23.
Higgins PG, et al. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother. 2012;67:1167–9.CrossRefPubMed
24.
25.
Mushtaq S, et al. Activity of BAL30072 alone or combined with beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother. 2013;68:1601–8.CrossRefPubMed
26.
27.
28.
Farrell DJ, et al. Antimicrobial activity of ceftolozane–tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–10.CrossRefPubMedCentralPubMed
29.
Farrell DJ, et al. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533–9.CrossRefPubMed
30.
Sader HS, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother. 2014;69:2713–22.CrossRefPubMed
31.
Personal communication of CUBIST Pharmaceuticals, December 17th 2014.
32.
33.
Lucasti C, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane–tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:5350–7.CrossRefPubMedCentralPubMed
34.
Maseda E, et al. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther. 2014;12:1–15.CrossRef
35.
Bretonniere C, et al. In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem. Int J Antimicrob Agents. 2014;44:218–21.CrossRefPubMed
36.
Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:649–58.CrossRefPubMedCentralPubMed
37.
Siala W, et al. Antibiotic activity against biofilms from Staphylococcus aureus clinical isolates: factors determining the activity of the investigational fluoroquinolone delafloxacin in comparison with daptomycin and vancomycin. Antimicrob Agents Chemother. 2014;58:6385–97.CrossRefPubMed
38.
39.
Oldach D, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013;57:2526–34.CrossRefPubMedCentralPubMed
40.
Van Bambeke F. Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Ann Med. 2014;46:512–29.CrossRefPubMed
41.
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline–avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010–2011. Antimicrob Agents Chemother. 2013;57:1982–8.CrossRefPubMedCentralPubMed
42.
Livermore DM, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55:390–4.CrossRefPubMedCentralPubMed
43.
44.
Hirsch EB, et al. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012;56:3753–7.CrossRefPubMedCentralPubMed
45.
Griffith DC, et al. A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 in health adult subjects, in 24th European congress of clinical microbiology an infectious diseases ECCMID 20142014: Barcelona.
46.
Nordmann P, et al. Characterisation of beta-lactamase inhibition by AAI101, an extended-spectrum beta-lactamase inhibitor, in 24th European congress of clinical microbiology an infectious diseases ECCMID 20142014: Barcelona.
47.
Locher HH, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58:892–900.CrossRefPubMedCentralPubMed
48.
Chilton CH, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014;69:697–705.CrossRefPubMed
49.
Baldoni D, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014;69:706–14.CrossRefPubMed
50.
Louie T, et al. Multicentre, double-blind, randomised, phase 2 study evaluating the novel antibiotic, cadazolid, in subjects with Clostridium difficile-associated diarrhoea. Abstract LB 2956, 22nd European congress of clinical microbiology and infectious disease, Berlin, April 27–30, 2013.
51.
Metadata
Title
Novel antibiotics: Are we still in the pre–post-antibiotic era?
Authors
R. Draenert
U. Seybold
E. Grützner
J. R. Bogner
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 2/2015
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0749-y

Other articles of this Issue 2/2015

Infection 2/2015 Go to the issue

Case Report

An unusual case of a large, sporadic intra-abdominal abscess due to group B Streptococcus and a review of the literature

Case Report

Nosocomial pneumonia caused by carbapenem-resistant Raoultella planticola: a case report and literature review

Images in Infection

Pulmonary and mediastinal tuberculosis in an immunocompetent child presenting as sternal abscess protruding from the skin

Case Report

Malignant syphilis in an AIDS patient

Erratum

Erratum to: Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS)

Correspondence

Serum-derived bovine immunoglobulin/protein isolate should be considered in patients with HIV gut barrier dysfunction

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits